139 related articles for article (PubMed ID: 32774771)
1. Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trial.
Oshima T; Yoshikawa T; Miyagi Y; Morita S; Yamamoto M; Tanabe K; Nishikawa K; Ito Y; Matsui T; Kimura Y; Yokose T; Hiroshima Y; Aoyama T; Hayashi T; Ogata T; Cho H; Rino Y; Masuda M; Tsuburaya A; Sakamoto J
Oncotarget; 2020 Jul; 11(30):2906-2918. PubMed ID: 32774771
[TBL] [Abstract][Full Text] [Related]
2. Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS trial.
Yoshikawa T; Tanabe K; Nishikawa K; Ito Y; Matsui T; Kimura Y; Hirabayashi N; Mikata S; Iwahashi M; Fukushima R; Takiguchi N; Miyashiro I; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J
Ann Surg Oncol; 2014 Jan; 21(1):213-9. PubMed ID: 23838904
[TBL] [Abstract][Full Text] [Related]
3. Digital histopathological images of biopsy predict response to neoadjuvant chemotherapy for locally advanced gastric cancer.
Zhou Z; Ren Y; Zhang Z; Guan T; Wang Z; Chen W; Luo T; Li G
Gastric Cancer; 2023 Sep; 26(5):734-742. PubMed ID: 37322381
[TBL] [Abstract][Full Text] [Related]
4. Primary results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for advanced gastric cancer.
Hayashi T; Yoshikawa T; Sakamaki K; Nishikawa K; Fujitani K; Tanabe K; Misawa K; Matsui T; Miki A; Nemoto H; Fukunaga T; Kimura Y; Hihara J
Ann Gastroenterol Surg; 2020 Sep; 4(5):540-548. PubMed ID: 33005849
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic analysis of neoadjuvant chemotherapy for locally advanced gastric cancer with propensity score matching method].
Peng L; Yang W; Zhang Z; Zhi C; Zhou X; Liu H; Hua Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1148-1153. PubMed ID: 30370514
[TBL] [Abstract][Full Text] [Related]
6. XPA expression is a predictive marker of the effectiveness of neoadjuvant chemotherapy for locally advanced uterine cervical cancer.
Wada T; Fukuda T; Shimomura M; Inoue Y; Kawanishi M; Tasaka R; Yasui T; Ikeda K; Sumi T
Oncol Lett; 2018 Mar; 15(3):3766-3771. PubMed ID: 29556276
[TBL] [Abstract][Full Text] [Related]
7. Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival.
Wang RX; Chen S; Huang L; Zhou Y; Shao ZM
Oncologist; 2019 Jun; 24(6):753-761. PubMed ID: 30126858
[TBL] [Abstract][Full Text] [Related]
8. A comparison of multimodality treatment: two or four courses of paclitaxel plus cisplatin or S-1 plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized Phase II trial (COMPASS).
Yoshikawa T; Tsuburaya A; Morita S; Kodera Y; Ito S; Cho H; Miyashita Y; Sakamoto J
Jpn J Clin Oncol; 2010 Apr; 40(4):369-72. PubMed ID: 20299499
[TBL] [Abstract][Full Text] [Related]
9. Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer.
Yoshikawa T; Morita S; Tanabe K; Nishikawa K; Ito Y; Matsui T; Fujitani K; Kimura Y; Fujita J; Aoyama T; Hayashi T; Cho H; Tsuburaya A; Miyashita Y; Sakamoto J
Eur J Cancer; 2016 Jul; 62():103-11. PubMed ID: 27244537
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.
Sarid D; Ron IG; Sperber F; Stadler Y; Kahan P; Kovner F; Ben-Yosef R; Marmor S; Grinberg Y; Maimon N; Weinstein J; Yaal-Hahoshen N
Clin Drug Investig; 2006; 26(12):691-701. PubMed ID: 17274676
[TBL] [Abstract][Full Text] [Related]
11. Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.
Fazio N; Biffi R; Maibach R; Hayoz S; Thierstein S; Brauchli P; Bernhard J; Stupp R; Andreoni B; Renne G; Crosta C; Morant R; Chiappa A; Luca F; Zampino MG; Huber O; Goldhirsch A; de Braud F; Roth AD; ;
Ann Oncol; 2016 Apr; 27(4):668-73. PubMed ID: 26712905
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer.
Tsuburaya A; Nagata N; Cho H; Hirabayashi N; Kobayashi M; Kojima H; Munakata Y; Fukushima R; Kameda Y; Shimoda T; Oba K; Sakamoto J
Cancer Chemother Pharmacol; 2013 May; 71(5):1309-14. PubMed ID: 23463482
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival outcomes of advanced gastric cancer patients who achieved a pathological complete response with neoadjuvant chemotherapy: a systematic review of the literature.
Cho H; Nakamura J; Asaumi Y; Yabusaki H; Sakon M; Takasu N; Kobayashi T; Aoki T; Shiraishi O; Kishimoto H; Nunobe S; Yanagisawa S; Suda T; Ueshima S; Matono S; Maruyama H; Tatsumi M; Seya T; Tanizawa Y; Yoshikawa T
Ann Surg Oncol; 2015 Mar; 22(3):787-92. PubMed ID: 25223927
[TBL] [Abstract][Full Text] [Related]
14. Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy.
Chou HH; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Yu MC; Lo YF; Dabora MA; Chang HK; Lin YC; Ueng SH; Chen SC
Biomed J; 2019 Feb; 42(1):66-74. PubMed ID: 30987708
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
16. Refining the Performance of Sentinel Lymph Node Biopsy Post-neoadjuvant Chemotherapy in Patients with Pathologically Proven Pre-treatment Node-positive Breast Cancer: An Update for Clinical Practice.
El Hage Chehade H; Headon H; Kasem A; Mokbel K
Anticancer Res; 2016 Apr; 36(4):1461-71. PubMed ID: 27069121
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Chemotherapy Alters Neuropilin-1, PlGF, and
Al-Zeheimi N; Naik A; Bakheit CS; Al Riyami M; Al Ajarrah A; Al Badi S; Al Baimani K; Malik K; Al Habsi Z; Al Moundhri MS; Adham SA
Front Oncol; 2019; 9():323. PubMed ID: 31106153
[TBL] [Abstract][Full Text] [Related]
18. PRMT1 expression predicts response to neoadjuvant chemotherapy for locally advanced uterine cervical cancer.
Shimomura M; Fukuda T; Awazu Y; Nanno S; Inoue Y; Matsubara H; Yamauchi M; Yasui T; Sumi T
Oncol Lett; 2021 Feb; 21(2):150. PubMed ID: 33552268
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake?
Reddavid R; Sofia S; Chiaro P; Colli F; Trapani R; Esposito L; Solej M; Degiuli M
World J Gastroenterol; 2018 Jan; 24(2):274-289. PubMed ID: 29375213
[TBL] [Abstract][Full Text] [Related]
20. [Results of Neoadjuvant Chemotherapy with S-1 plus CDDP for Gastric Cancer-The Number of Therapeutic Coursers and Therapeutic Effects].
Takiguchi N; Nabeya Y; Ikeda A; Soda H; Tonooka T; Hoshino I; Gunji H; Kawahara K
Gan To Kagaku Ryoho; 2019 Dec; 46(13):2107-2109. PubMed ID: 32156847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
